Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma

• DOI: 10.18632/oncotarget.28147
• Publication Date: 2021-12-07T16:35:33Z
• Authors: Sarah Adriana Scu...; Giovanna Casili; Alessia Filippone; Marika Lanza; Rossella Basilotta; Raffaella Giuffrida; Stefania Munaò; Lorenzo Colarossi; Anna Paola Capra; Emanuela Esposito; Irene Paterniti
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Angiogenesis; Apoptosis; Oral squamous cell carcinoma (OSCC); Prolyl-oligopeptidase (POP); Tongue squamous cell carcinoma (TSCC); Research Paper; 3. Good health

Oral squamous cell-carcinoma (OSCC) is a common cancer which arises from the alveolar ridge, buccal mucosa, and tongue. Among OSCC, incidence of tongue (TSCC) growing all over world. carcinogenesis has been linked to genetic mutations, chromosomal aberrations viral factors. Apoptosis angiogenesis play key role in development oral cancer. Therefore, it very important discover new therapeutic strategies counteract progression. This study aimed investigate effect KYP-2047 an vitro model TSCC vivo CAL27-xenograft model. Our results demonstrated that was able reduce TSCCs cell viability at concentrations 50 μM 100 μM. Additionally, increase Bax, Bad caspase-3 expression, whereas Bcl-2 p53 expression were reduced. Moreover, significantly reduced vascular-endothelial-growth-factor (VEGF) endothelial-nitric-oxide-synthase (eNOS) expression. In xenograft model, doses 1 5 mg/kg tumor burden weight, decreasing also markers VEGF eNOS. increased Bax Bcl2 expressions. Thus, could represent potential treatment oral-cancer growth, thanks its abilities modulate apoptosis pathways.